Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: September 15, 2005
Last updated: January 31, 2012
Last verified: January 2012
As a result of the recent supply shortages in the U.S., as well as an anticipated increase in demand during the coming years, GSK Biologicals is pursuing licensure of Fluarix in the U.S. under the accelerated approval process; marketing approval most likely will be granted before the start of this clinical trial. GSK proposes to support U.S. licensure of Fluarix with this confirmatory post-marketing study. The purpose of the study is to evaluate the efficacy of a single dose of Fluarix in preventing influenza in adults during the 2005/2006 Influenza season.

Condition Intervention Phase
Biological: Influenza vaccine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Double-blind, Placebo-controlled, Post-marketing Phase III Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine (Fluarix™) Administered Intramuscularly in Adults.

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Incidence of culture confirmed influenza A and/or B during the surveillance period

Secondary Outcome Measures:
  • Efficacy: Incidence of ILI, Number of days of fever, days of school/work absenteeism, hospitalization related to influenza illness, Incidence of pneumonia, Incidence of PCR confirmed influenza A and/or B

Enrollment: 6213
Study Start Date: September 2005
Study Completion Date: October 2005
Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • A male or female age between, and including, 18 and 64 years of age at the time of the vaccination.
  • Written informed consent obtained from the subject.
  • Availability to follow up by phone during the study period.
  • Female subjects must be of non-childbearing potential, i.e. either surgically sterilized or one year post-menopausal. If subject is of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination. She must also have a negative pregnancy test at study entry and must agree to continue such precautions for two months after vaccination.

Exclusion Criteria:

  • History of hypersensitivity to a previous dose of influenza vaccine.
  • History of allergy or reactions likely to be exacerbated by any component of the vaccine including egg, chicken protein, formaldehyde, thimerosal, gentamicin sulfate or sodium deoxycholate.
  • Acute disease at the time of enrollment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever). All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e. Oral temperature < 37.5°C).
  • Pregnancy
  • Chronic disorders of the pulmonary or cardiovascular system, including asthma
  • History of requiring regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00197223

Czech Republic
GSK Investigational Site
Hradec Kralove, Czech Republic, 500 03
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Abstract presented at the Tenth Annual Conference on Vaccine Research sponsored by the National Foundation for Infectious Diseases. April 30 - May 2, 2007. Baltimore, MD, US. Jiri Beran1,2, Veronika Wertzova1, Karel Honegr2, Eva Kaliskova3, Martina Havlickova4, Jiri Havlik1, Helena Jirincova4, Pascale Van Belle5, Varsha Jain6, Jeanne-Marie Devaster5, Bruce Innis6, A prospective placebo controlled vaccine efficacy study with Fluarix®* during a mild influenza season with primarily drifted B strain circulation. 1The Vaccination and Travel Medicine Center, 2Department of Infectious Diseases, University Hospital, Hradec Kralove, and 4National Institute for Health National: Reference Laboratory for Influenza, Praha; Czech Republic; GlaxoSmithKline Biologicals, 3Praha, Czech Republic, 5Rixensart, Belgium and 6King of Prussia, USA

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure Identifier: NCT00197223     History of Changes
Other Study ID Numbers: 104438 
Study First Received: September 15, 2005
Last Updated: January 31, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on September 23, 2016